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and physiological interactions of 
nanosized drug carriers are also 
discussed.
d
issertatio
n
s | 252 | Ju
ssi R
ytk
ö
n
en
Jussi Rytkönen
Mesoporous silicon particles 
designed for nanomedical 
applications
JUSSI RYTKÖNEN
Mesoporous silicon particles  
designed for nanomedical  
applications
Mesoporous silicon particles designed for
nanomedical applications



JUSSI RYTKÖNEN
Mesoporous silicon particles designed for
nanomedical applications
To be presented by permission of the Faculty of Health Sciences, University of Eastern Finland for
public examination in SN201, Kuopio, on  December 5th  2014, at 12 noon
Publications of the University of Eastern Finland
 Dissertations in Health Sciences
Number 252
School of Pharmacy, Faculty of Health Sciences,
University of Eastern Finland
Kuopio
2014
Printing Office
Kuopio, 2014
Series Editors:
Professor Veli-Matti Kosma, M.D., Ph.D.
Institute of Clinical Medicine, Pathology
Faculty of Health Sciences
Professor Hannele Turunen, Ph.D.
Department of Nursing Science
Faculty of Health Sciences
Professor Olli Gröhn, Ph.D.
A.I. Virtanen Institute for Molecular Sciences
Faculty of Health Sciences
Professor Kai Kaarniranta, M.D., Ph.D.
Institute of Clinical Medicine, Ophthalmology
Faculty of Health Sciences
Lecturer Veli-Pekka Ranta, Ph.D. (pharmacy)
School of Pharmacy
Faculty of Health Sciences
Distributor:
University of Eastern Finland
Kuopio Campus Library
P.O.Box 1627
FI-70211 Kuopio, Finland
http://www.uef.fi/kirjasto
ISBN (print): 978-952-61-1593-1
ISBN (pdf): 978-952-61-1594-8
ISSN (print): 1798-5706
ISSN (pdf): 1798-5714
ISSN-L: 1798-5706
III
Author’s address: School of Pharmacy
University of Eastern Finland
KUOPIO
FINLAND
Supervisors: Adjunct Professor Ale Närvänen, Ph.D.
School of Pharmacy
University of Eastern Finland
KUOPIO
FINLAND
Professor Vesa-Pekka Lehto, Ph.D.
Department of Applied Physics
University of Eastern Finland
KUOPIO
FINLAND
Adjunct Professor Jarno Salonen, Ph.D.
Department of Physiscs and Astronomy
University of Turku
TURKU
FINLAND
Professor Jouko Vepsäläinen, Ph.D.
School of Pharmacy
University of Eastern Finland
KUOPIO
FINLAND
Reviewers: Associate Professor Kensuke Osada, Ph.D.
Department of Bioengineering
The University of Tokyo
TOKYO
JAPAN
Docent Jessica Rosenholm, D.Sc.(Tech.)
Department of Physical Chemistry
Åbo Academi University
TURKU
FINLAND
Opponent: Docent Oula Peñate-Medina, Ph.D.
Department of Diagnostic Radiology
The University of Kiel
KIEL
GERMANY
IV
VRytkönen Jussi
Mesoporous silicon particles designed for nanomedical applications
University of Eastern Finland, Faculty of Health Sciences
Publications of the University of Eastern Finland. Dissertations in Health Sciences Number 252. 2014. 48 p.
ISBN (print): 978-952-61-1593-1
ISBN (pdf): 978-952-61-1594-8
ISSN (print): 1798-5706
ISSN (pdf): 1798-5714
ISSN-L: 1798-5706
ABSTRACT
It is predicted that nanomedicines will make substantial contributions to pharmacy and
medicine  in  the  near  future;  one  important  application  will  be  their  use  as  drug  carriers.
Many conventional drugs suffer from drawbacks, such as low solubility, rapid metabolism
or severe side-effects. It is possible that nanosized drug carriers can overcome the problems
with poor solubility and stability. Furthermore, the side-effects can be reduced as the
nanocarrier can be specifically guided to the tissue of interest.
Mesoporous silicon (PSi) is a suitable material for drug delivery purposes since it is
highly biocompatible as PSi dissolves into the nontoxic orthosilisic acid which is excreted in
the urine. The high pore volume and surface area of the material mean that the carrier has a
high drug loading capacity. Furthermore, by adjusting the porosity and surface chemistry
the release rate of the loaded drug and the degradation of PSi itself can be tuned. A
functionalised carrier can utilise information about the disease and the patient to help in
achieving tailor-made therapeutics. Combining therapy and diagnostic imaging i.e.
“theranostics” allows one type of medical personalisation, which is becoming increasingly
important in modern cancer treatment.
In this study, the PSi nanoparticles were modified and used as drug carriers for different
types of therapeutic agents, i.e. peptides, oligonucleotides and anti-cancer drugs. The
carrier surface was optimised to reduce the interaction with plasma proteins. For imaging
purposes, a simple radiolabelling method was developed along with a conjugation
procedure for other bioactive or targeting molecules. A pH-dependent release of anticancer
drug was achieved from the carrier and the pharmacokinetics of the peptides changed
when they were administered within PSi drug carriers after intravenous administration.
Suprisingly, the PSi-nanoparticles were observed to exert adverse effects on the
cardiovascular system of the treated animals. In an attempt to achieve intracellular
delivery, the PSi drug carrier was combined with cell penetrating peptides to promote the
delivery of oligonucleotides i.e. agents which do not normally cross biological membranes.
Importantly, the peptides and oligonucleotides maintained their biological function after
they were released from the carrier.
As PSi nanoparticles are applicable for several types of therapeutic molecules, they can
be considered as versatile drug delivery carriers with diverse nanomedical applications.
However, the biological environment is extremely complex and the translation of
nanosized drug carriers into clinical use has proved difficult due to poor in vitro and in vivo
correlations. Therefore, one needs to optimise and characterise the interactions between the
nanocarrier and the biological environment when nanoformulations are being developed
for clinical use.
National Library of Medicine Classification: QT 36.5, QV 778, QV 785
Medical Subject Headings: Nanomedicine; Nanoparticles; Nanostructures; Silicon; Drug Carriers; Drug
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TIIVISTELMÄ
Nanolääkkeet ja erityisesti lääkeainekantajat voivat edesauttaa lääketiedettä
tulevaisuudessa. Useat perinteiset lääkeaineet kärsivät huonosta liukoisuudesta, liian
nopeasta metaboliasta tai haitallista sivuvaikutuksista. Nämä ongelmat voidaan välttää
käyttämällä nanokokoisia lääkeainekantajia, jotka voivat parantaa lääkeaineen liukoisuutta
ja stabiilisuutta. Sivuvaikutuksia voidaan vähentää kohdentamalla lääkeainekantajat
haluttuun kudokseen.
Mesohuokoinen pii (PSi) soveltuu lääkeainekuljetinmateriaaliksi bio-
yhteensopivuutensa ansiosta. Elimistössä PSi liukenee vaarattomaksi piihapoksi, joka
poistuu virtsan mukana. PSi:n suuri huokoisuus ja pinta-ala mahdollistavat suuren
lääkeainelatauskapasiteetin. Säätelemällä huokosten kokoa ja PSi:n pintakemiaa voidaan
vaikuttaa sekä lääkeaineen vapautumisnopeuteen että itse kantajan liukoisuuteen.
Erilaisten toimintojen lisääminen kantajaan mahdollistaa yksilöllisesti räätälöidyn
lääkehoidon. Yhdistämällä lääkeaineiden kuljetus ja lääketieteellinen kuvantaminen (engl.
theranostics) voidaan edesauttaa henkilökohtaisen lääketieteen kehittämistä, mikä on
tuleva trendi syöpähoidoissa.
Tässä väitöskirjatutkimuksessa PSi-nanopartikkeleita muokattiin lääkeainekantajiksi
erilaisille terapeuttisille molekyyleille, kuten peptideille, oligonukleotideille ja
syöpälääkkeille. Lääkeainekantajan pintaa muokattiin vähentämään vuorovaikutusta veren
proteiinien kanssa. Kuvantamista varten kehitettiin radioleimausmenetelmä sekä
menetelmä, jolla voidaan kiinnittää bioaktiivisia ja kohdentavia molekyylejä PSi-kantajan
pintaan. Lisäksi kantajalla saatiin muutettua peptidihormonien farmakokinetiikkaa
suonensisäisen annostelun jälkeen. Toisaalta PSi-kantajalla todettiin olevan lyhytaikaisia
haitallisia vaikutuksia koe-eläinten verenkiertojärjestelmään. Oligonukleotidien kuljetus
solujen sisään onnistui yhdistämällä PSi-kantaja solukalvon läpäisevään peptidiin.
Huomionarvoista oli, että peptidi ja oligonukleotidi säilyttivät biologisen toimintakykynsä
vapauduttuaan PSi-kantajasta.
Koska PSi:tä voidaan hyödyntää kantajana erityyppisille terapeuttisille molekyyleille, se
on hyvin monikäyttöinen lääkeainekantajamateriaali, jolla on käyttöä useissa
nanolääketieteen sovellutuksissa. Biologinen toimintaympäristö on kuitenkin erittäin
monimutkainen ja nanokokoisten lääkeainekantajien siirtäminen yleiseen lääketieteeseen
onkin osoittautunut haastavaksi huonon in vitro- ja in vivo-korrelaation vuoksi.
Kehitettäessä nanomateriaaleja kliinisen lääketieteen tarpeisiin, on tärkeää tunnistaa
vuorovaikutukset lääketieteellisten nanomateriaalien ja biologisen ympäristön välillä.
Luokitus: QT 36.5, QV 778, QV 785
Yleinen Suomalainen asiasanasto: nanotekniikka; nanorakenteet; nanohiukkaset; huokoisuus; pii; lääkkeet;
lääkeaineet; peptidit; oligonukleotidit; solunsalpaajat; sivuvaikutukset
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11 Introduction
According to the IUPAC definition, a “nanoparticle” is a particle of any shape with
dimensions in the range of 1 nm – 100 nm (Vert et al. 2012). However, the prefix “nano” is
accepted for dimensions smaller than 500 nm in other phenomena, such as stable
dispersion. The small size confers interesting and unique physical and chemical properties,
such as the quantum confinement and the resulting photoluminescence in quantum dots
and in porous silicon (Barbagiovanni et al. 2014). These interesting properties can be
beneficial for nanomedical devices i.e. for imaging purposes. The size also means that they
have a huge surface area and can undergo novel biological interactions, which must be
understood before the full potential of nanomaterials can be exploited.
Nanomedicines are submicrometer-sized carrier materials designed to improve the
biodistribution and the target site accumulation of systemically administered therapeutic
agents (Lammers et al. 2011). Chemotherapy is notorious for its harsh side-effects with
conventional anti cancer drugs. However, drug carriers are seen as an opportunity to
improve the patient experience and the dosage of the drugs in cancer treatment.  In
addition to chemotherapy, drug delivery can facilitate the use of other types of drug
molecules e.g. those which suffer from low bioavailability or too rapid metabolism. Thus,
the potential of new carrier materials has been widely acknowledged (Wacker 2013).
The utilization of nanomaterials in nanomedicine has led to several new innovations.
Not only can they be used for drug delivery, but the nanosized carriers can also be used for
imaging. “Theranostics” combines therapeutic drug delivery and diagnostic imaging (Sun
2010). It has been claimed that theranostics holds significant potential for personalizing
nanomedicine based treatment of cancer (Lammers et al. 2012b). Every cancer/patient is
genetically unique and the variation between patients may be extensive, even though their
symptoms may appear similar. Therefore, there are hopes that the personalization of cancer
therapy can represent a route for more efficient treatment (Papadopoulos, Kinzler &
Vogelstein 2006, Messersmith, Ahnen 2008). Cancer is an evolutionary disease running a
life-and-death race against the body’s own defence mechanisms and anti-cancer treatments.
The continuous mutations and adaptation efficiency reflects the enormous diversity within
the tumour itself and explains why cancer is so hard to cure (Merlo et al. 2006). The number
of published research articles regarding drug delivery with nanomaterials has skyrocketed
in the new millennium, a reflection of their potential for the pharmaceutical industry. On
the other hand, although the very first liposomal drugs have been on the market for almost
20 years, approval of new nanomedicines has been relatively slow. Although targeted
nanocarriers are being widely investigated troughout the scientific community and some
recently developed formulations are in clinical trials, there are no nanodrugs based on
targeted delivery on the market at present (Jin, Jin & Hong 2014, Ferrari 2013). In fact, there
are still many barriers to be overcome before “the magic bullet” of nanomedicine will be
ready to enter the clinics.
Mesoporous silicon (PSi) nanomaterial has attracted considerable attention since it
possesses suitable properties for biomedical applications (Santos et al. 2014). This thesis will
address the use of porous silicon (PSi) nanocarriers in nanomedical applications, including
targeted drug delivery and imaging using different modalities.
21.1 POROUS SILICON NANOMATERIALS
Porous silicon (PSi) is an anisotropic form of elemental silicon with a complex pore
morphology and crystalline nanostructure. The most beneficial recognised properties of PSi
are large surface area, photoluminescence, biocompatibility and versatile surface chemistry.
While the field of nanothechnology is a relatively novel research area, PSi was discovered
almost 60 years ago. The first description of porous silicon produced by electrochemical
etching was published in the 1950s by Uhlir in Bell Laboratories (Uhlir 1955). While trying
to electropolish the surface of bulk silicon, Uhlir observed the formation of a matte black,
brown or red deposit on the surface of etched silicon. The nature of this deposit was
studied further by Watanabe in the 1970s, who discovered its porous structure (Watanabe,
Sakai 1971). Subsequently, it was found out that the pore formation during etching was
dependent on the crystal orientation in the silicon substrate (Theunissen 1972). Originally
PSi was studied in relation to its potential in semiconductor technology, until Canham
described the photoluminescent properties of PSi (Canham 1990). PSi emits photons at
visible wavelengths when excited with a laser. The photoluminescence is most likely based
on the quantum confinement within the nanocrystallites and the pore wall in PSi material
(Sailor, Lee 1997). The foundations of the biomedical applications of PSi were laid when
Canham demonstrated that PSi was bioactive (Canham 1995). Although crystalline bulk
silicon is considered to be poorly biocompatible, PSi can be modified bioinert, bioactive or
biodegradable depending on the porosity and the pore size of the material (Canham 1997).
The biocompatibility of the material was further demonstrated when it was found that
living cells could grow on a PSi surface (Bayliss et al. 1999).
1.1.1 Preparation of porous silicon
The drawback of PSi is the lack of industrial scale preparation methods and therefore the
relatively high cost of the material. The normal laboratory technique to prepare PSi requires
anodical etching of a silicon wafer in a mixture of hydrofluoric acid (HF) and ethanol
(EtOH). The etching vessel has to be constructed of an inert material e.g.
polytetrafluoroethylene (PTFE) because glass would be dissolved by HF. EtOH is usually
added as a surfactant to the electrolyte, as this reduces the size of hydrogen bubbles being
formed during the etching. PSi can be considered as an anode in this system as the actual
metallic anode is not touching the electrolyte solution. The electric current promotes
etching which starts from small defects on silicon wafer contributing to the formation of
parallel pores (Figure 1 A). In principle, crystalline silicon is oxidized to soluble silicon
hexafluoride.  There are various parameters that can affect how etching is performed e.g.
the concentration of dissolving HF and surfactant EtOH in the electrolyte solution, the
etching current  density,  the  orientation of  the  silicon crystal,  doping polarity  (n, p) of the
silicon substrate, and the amount of the doping agent (Thomas 2000, Lehmann, Föll 1990).
By changing these etching parameters, one is able to gain control over the pore formation
i.e. shape, size and overall porosity. After the etching, the system can be subjected to a high
current electropolishing pulse which detaches the formed PSi film from the substrate.
Subsequently, the PSi film can be surface-stabilised and modified further in addition to
grinding into particles with ball-milling as well as fractioning with centrifugation or sieving
(Figure 1 B). In contrast to the preparation of porous silica particles, well characterised
silicon based porous material where the particles are formed, via a bottom-up process, from
a solute, PSi preparation utilises a top-down method where the particles are prepared from
a bulk material.
3Stain etching, i.e. chemical etching, is another way to prepare of PSi which does not
require any electrical current. The first stain etches were grown on silicon surface in dilute
nitric acid (HNO3) and concentrated HF in the 1950s (Fuller, Ditzenberger 1956).  The
formation of stain films was also observed on silicon wafer when they were eched with
HNO3/HF/H2O solution (Archer 1960, Turner 1960). Later the photoluminescence
properties of the stains were appreciated and the material was observed to be similar to
anodic etched PSi (Shih et al. 1992, Fathauer et al. 1992). Noetheless, anodically etched PSi is
preferred to stain etched PSi because anodical etched form is a more crystalline material as
compared to the amorphous stain etched version (Fathauer 1994). Furthermore, anodic
etching provides greater control over the layer thickness, pore size and porosity (Salonen et
al. 2008).
Figure 1 Cross section of a simplified etching vessel for the preparation of PSi. A thin film of PSi
is formed on the upper surface of silicon wafer by anodic electrochemical etching in HF/EtOH
solution (A). PSi nano- and microparticles are prepared by milling the PSi film which are then
size fractioned with centrifugation. Possible surface functionalisation can be done either for films
or particles (B).
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41.1.2 Surface stabilisation
The freshly etched PSi consists of silicon hydrides (Figure 2A). It is very reactive and will
oxidize in ambient conditions within minutes (Salonen et al. 2008). Thus, several methods
have been developed to stabilise the PSi surface, including thermal oxidation,
hydrosilylation, thermal carbonisation and thermal hydrocarbonisation.
In some cases, oxidation of PSi is a desired event, because controlled oxidation stabilises
the surface and converts the hydrophobic hydrogen terminated surface into a more
hydrophilic structure of silicon oxides and hydroxides (Figure 2B). Furthermore, it
stabilises the photoluminescence of the material. There are multiple methods available for
oxidation of a PSi surface including thermal-, photo-, anodic- and chemical oxidation
(Salonen, Lehto & Laine 1997, Halimaoui, Oules & Bomchil 1991, Salonen, Lehto & Laine
1999, Nakajima et al. 1992). The most important surface stabilisation method with respect to
this thesis is thermally oxidated porous silicon (TOPSi).
Hydrosilylation is an addition reaction for silicon hydride with unsaturated carbon
bond. Hydrosilylation can stabilise the PSi surface by producing silicon hydrocarbon
structures (Figure 2C).  There are several was to achive hydrosilylation described in the
literature, e.g. photoinduced and Lewis acid hydrosilylation (Stewart, Buriak 1998, Buriak
et al. 1999). However, the efficiency with these methods remains relatively low, only 28% at
best (Buriak et al. 1999). The efficiency of hydrosilylation can be improved by using
elevated temperatures i.e. in thermal hydrosilylation, approximately 70% of the hydrogen
groups react (Boukherroub et al. 2000). The better efficiency improves the stability of the
material against oxidation as thermally hydrosilylated PSi remains stable in 100% relative
humidity at 70 °C for several weeks. Furthermore, PSi retains its photoluminescence after
thermal hydrosilylation. In addition to improved stability, thermal hydrosilylation
represents a convenient method for functionalisation of PSi surface with carboxylic acid
groups (Boukherroub et al. 2002). In subsequent studies, it has been found that
hydrosilylation can happen through several mechanistic pathways, including plasmon,
photoemission, exitons and radical reactions (Buriak 2013). Another method to incorporate
Si-C bonds onto the silicon surface is achieved after halogenating the silicon hydride
surface with phosphorus pentachloride and applying Grignard-reaction for alkylation
(Bansal et al. 1996).
Thermal carbonisation of PSi (TCPSi) produces silicon carbide on the surface of PSi
(Figure 2D). The technique employs the absorption and decomposition of acetylene gas
onto the PSi surface at high temperatures (Salonen et al. 2000). This treatment improves the
stability of the material against humid and thermal oxidation. TCPSi has also improved
mechanical and chemical resistance and the material possesses better thermal and electrical
conductivity but it seems to lose all of its photoluminescence (Salonen, Laine & Niinistö
2002). However, the restoration of quenched photoluminescence of TCPSi has been studied
by extending the acetylene flow after the carbonization process (Lakshmikumar, Singh
2002). The extent of carbonisation can be controlled with temperature and can range from
partial carbonisation to the formation of graphite-like structures (Salonen, Laine & Niinistö
2002). When lower temperatures are used in the treatment, hydrogen is not desorbed and a
very hydrophobic thermally hydrocarbonised PSi (THCPSi) surface is formed (Salonen et
al. 2004). This type surface is also resistant towards oxidation and chemical degradation
(Figure 2 E).
5Figure 2 Examples of possible surface stabilisations of PSi. Freshly etched PSi surface is
metastable silicon hydride (A). When PSi surface is oxidised silicon oxides and –hydroxides are
formed. Back bond oxidation takes place between Si-Si bonds (B). Hydrosilylation reaction
replaces the Si-H bond with more stable Si-C. It also provides a means for surface
functionalisation of PSi (C). Thermal carbonisation forms a layer of extremely resistant silicon
carbide, even graphite, on the PSi surface. For clarity, only a few of the carbon atoms are
marked and some of the carbon bonds are not drawn (D). Thermal hydrocarbonisation is
produced at lower temperatures and in that case the surface remains very hydrophobic (E).
1.1.3 Surface functionalisation
In addition to surface stabilisation of PSi, further modification of the surface is necessary
prior to biomedical and sensor technological usage (Dhanekar, Jain 2013). The conjugation
of imaging and targeting moieties is facilitated by the presence of functional groups on the
surface. Furthermore, shielding of the particles surface from binding to plasma proteins is
very important id they are to be administered intravenously. The surface functionalisation
makes possible a diversity of surface conjugations as molecules can be either directly
conjugated to the surface or introduced stepwise with additional reactions to reactive
groups introduced previously.
The functionalisation of the PSi surface can usually be achieved via two different
approaches. The first approach is the previously mentioned thermal hydrosilylation. The
second is to resort to alkyl silane chemistry, which allows the conjugation of molecules onto
the OH-group rich PSi surface. The most commonly used silane reagents contain amino
groups for further surface functionalisation (Davis et al. 2002). There are also some other,
less popular, surface modification techniques, e.g. photo- and radical reactions; these have
been reviewed elsewhere (Sailor, Lee 1997, Stewart, Buriak 2000).
Examples of surface functionalisation and conjugation of further moieties are listed in table
1. The latest trends in PSi functionalisation include solid lipid coating or polymeric coating
on the PSi core (Liu et al. 2013b, Shahbazi et al. 2014). PSi films have also been
functionalised on selective sites i.e. functionalised only on the pore openings with the pores
being left unfunctionalised (Wu, Sailor 2013).
6Table 1. Examples of surface functionalisation of porous silicon materials.
Functionalisation Reactions Form of PSi Reference
Amino Silane
Film,
Particle
Davis et al. 2002,
Mäkilä et al. 2012,
Xu et al. 2012b
Carboxylic acid to THCPSi
Radical coupling,
Hydrosilylation
Film,
Particle
Sciacca et al. 2010
Kovalainen et al.
2012b
PEGylation
Silane,
Click
Film
Low et al. 2006,
 Britcher et al. 2008
Protein A Silane Film Dancil, Greiner &Sailor 1999
Targeting peptide/ Click Particles Wang et al. 2014
Antibody conjugation Carbodiimide / N-hydroxysuccinimide Particles
Rytkönen et al.
2012
71.2 DRUG DELIVERY WITH NANOCARRIERS
1.2.1 Intravenous route and passive targeting
The rationale for the use of nanocarriers in drug delivery is to improve the drugs
distribution and enhance their efficacy. In principle, the drug carriers accumulate in the
determined area and release their cargo in a controlled manner. Nanomaterials designed
for drug delivery and imaging are likely to require intravenous injection because they
translocate poorly from the intestinal tract to the vascular system and from there to all
organs within the body. There are many barriers to be crossed before nanocarriers reach the
targeted cells, i.e. the barriers of the immune system, the vascular endothelium and the cell
membranes. The very first U.S. Food and Drug Adninistration approved nano-drug entered
the market in 1995 (Barenholz 2012). Doxil®, a liposome formulated doxorubicin, is based
on passive targeting, i.e. it does not contain any targeting ligand and it accumulates into the
tumour passively over time.
The aggressive and uncontrolled growth of the tumour combined with the enhanced
secretion of growth factors promoting angiogenesis can cause the tumour vasculature to be
poorly constructed (Maeda et al. 2000). The endothelium of these vessels is defective with
large fenestrations into the lumen of the tumour. Furthermore, in most cases, the tissue
lacks lymphatic drainage. The enhanced permeation and retention effect (EPR) takes
advantage of the compromised fluid dynamics in the tumour tissue which allows the
nanosized objects to penetrate from the bloodstream through the leaky vasculature and
fenestrations of the endothelium into the lumen of tumour tissue (Iyer et al. 2006).
Subsequently, the poor lymphatic drainage promotes the retention of these objects within
the tumour. The EPR effect can increase the local concentration of polymeric drugs, e.g.
therapeutic proteins conjugated to large molecular weight polymers, at the tumour site as
much as 10-50 times higher than in the normal tissues within 1-2 days (Iyer et al. 2006).  It is
the fundamental reason why passive targeting of anti-cancer nanocarriers can be effective
against solid tumors. However, EPR is dependent on several factors in the tumour
pathophysiology including the heterogenicity of the tumour tissue and the size of the
metastasis. An investigation of the accumulation of different sized polymeric micelles into
tumours with different permeabilities revealed that the EPR effect could improve the
accumulation of <100 nm nanoparticles into highly permeable tumours, whereas poorly
permeable pancreatic tumours expressed an EPR effect only with smaller nanoparticles (30
nm) (Cabral et al. 2011). Additionally, some metastatic cancers do not exhibit the EPR effect
at all (Maeda 2012, Fang, Nakamura & Maeda 2011).  Despite these limitations, EPR is a
relevant physiological phenomenon in anti-cancer drug delivery.
1.2.2 Active targeting and stimuli responsive drug delivery
The addition of a targeting ligand into the nanoparticle can improve the accumulation of
the particles into the desired tissue.  Targeting of nanomaterials can further benefit tumour
detection as the nanoformulations are able to enhance the sensitivity and specificity of the
imaging (Cao et al. 2014).  Furthermore, the specific interaction between targeting ligand
and the target can achieve the selection of diseased cells in preference to their healthy
counterparts which is and advantage in cancer therapy. Over the years several examples of
active targeting of various nanoparticle types have been described in the literature. The
targeting ligands include antibodies, affibodies, aptamers, peptides, proteins and small
molecules (Han, Davis 2013, Alexis et al. 2008, Farokhzad et al. 2004, Park et al. 2009b,
Huang et al. 2007, Rosenholm et al. 2008, Yoo et al. 2012).
However, it is essential to be aware of the main limiting factors of targeted drug delivery
i.e. selectivity vs. accumulation, reduced circulation time due to nanoparticle-protein
interactions and poor tissue penetration of nanomedicines.
8At first it should be noted that the expression “active targeting” is actually misleading
since the targeting ligand does not actively guide the particles but only enables specific
interaction with its target. The specific interaction can either promote cellular uptake or
simply prolong the duration of the interaction with the target cell. Ultimately, active
targeting is intended to improve target cell recognition, not to improve the over-all tumour
accumulation (Lammers et al. 2012a). Nonetheless, an optimal circulation time in the
bloodstream is still essential for the nanocarrier in order that it can be accumulated into the
targeted tissue.
The second problem involves the targeting ligands and their interactions with the
biological environment. Once a nanomaterial enters into a biological environment e.g. the
blood, it changes to becoming a hybrid material coated with plasma proteins (Mahmoudi et
al. 2011). The cells and tissues “see” only this hybrid material which is completely different
from the original surface of the nanomaterial. The formation of a protein corona around the
particle in biological fluids hinders the targeting functionality of the particles (Salvati et al.
2013). However, protein binding does not completely eradicate the targeting function of the
nanocarrier, as PSi nanoparticles targeted with antibodies have been able to bind to their
target protein in human plasma (Rytkönen et al. 2012). On the other hand, small molecular
ligands are more attractive for targeting in drug delivery due to their weaker immune
responses and the subsequent removal by the immune system (Gao, He 2014b).  A recent
study noted that polymeric nanocarriers, targeted with tumour homing peptide,
accumulated more rapidly into the tumour than non-targeted nanocarriers (Kunjachan et
al. 2014). However, over time the passive targeting of non-targeted nanocarriers was
significantly more efficient in comparison to actively targeted nanocarriers, leading to
higher levels and longer retention times in tumour. The reduced circulation time of the
targeted nanocarriers is due to the increased recognition of nanoparticles by the immune
system (Ruoslahti, Bhatia & Sailor 2010). Thus, a careful analysis of the impact of the
targeting ligand on the properties of the nanocarrier must be conducted and a balance
between long circulation time and targeting efficacy has to be found.
The third problem of targeted drug delivery is the poor penetration of nanomedicines
from the lumen of the blood vessel into the tumour interstitium (Ruoslahti, Bhatia & Sailor
2010). Targeted nanocarriers have to penetrate through the vascular endothelium if they are
to gain access to the tumour interstitium and on to the cancer cell at which they are
targeted. Several factors hinder the penetration of nanomedicine deeper into to tumour
tissue including the presence of interstitial matrix and the increased interstitial pressure
(Heldin et al. 2004, Jain, Stylianopoulos 2010). The EPR effect allows some leakage into the
tumour lumen, but it is not very effective and does not function in all cases. However, the
tumour vessels express a variety cell surface and extracellular matrix proteins that are
expressed at lower levels or are completely absent in normal blood vessels. Peptides,
targeted to -integrins (specifically 3 and 5) have been successfully utilised in
tumour targeting (Arap, Pasqualini & Ruoslahti 1998, Schiffelers et al. 2004). A tumour
homing peptide which targets the mammary derived growth factor has been utilized to
target PSi nanoparticles into the tumour in an animal model (Kinnari et al. 2013). These
tumour  blood  vessel  markers  have  been  described  in  detail  in  the  review  prepared  by
Ruoslahti (Ruoslahti 2002). Controversially, the poor penetration of the nanomedicine can
also be caused by exessively high affinity of the targeting antibody (Adams et al. 2001). One
possibility to improve the tumour penetration with active targeting involves the use of
tumour penetrating peptides. These rely on active transport through a neutropilin-1-
mediated mechanism and are able to penetrate deep into the extravascular tissue from the
blood vessel (Teesalu et al. 2009). A fusion peptide iRDG, combining -integrin targeting
and neutropilin-1 mediated tumour penetration has been utilized in drug delivery and
imaging (Sugahara et al. 2009, Wang et al. 2013). The recent paper of the group of Sántos,
described the utilisation of iRDG peptide on PSi nanoparticles for cancer cell targeting and
9internalization in vitro (Wang et al. 2014). Irrespective of these problems, targeted drug
delivery has the potential for the clinical use and several formulations are in phase I clinical
trials (Jin, Jin & Hong 2014).
A completely different approach to avoid poor tissue penetration of the nanocarriers is to
have a stimulus responsive release of the drug from the nanocarrier. Doxorubicin loaded
micelles, which release the cargo upon external heating at the tumour site, are able to
increase substantially the drug concentration within the tumour (Yarmolenko et al. 2010).
The release of doxorubicin takes place in the bloodstream and a high local concentration of
the drug can be achieved in the tumour tissue without having to cross the epithelium with
the nanocarrier.  Other studies have described the utilization of the acidic extracellular pH
or the presence of endogenous proteases in the tumour tissue to trigger the drug release
from the nanocarriers (Ko et al. 2007, Singh et al. 2011). These methodologies can reduce the
drug release in healthy tissue, but they still rely heavily on EPR to penetrate from the veins
to tumour interstitium.
1.2.3 Intracellular targeting
In the case of large and charged therapeutic molecules, such as plasmid DNA (pDNA),
small interfering RNA (siRNA) or antisense oligonucleotides, micro RNA and some protein
drugs, the therapeutic molecules need to be delivered into the cytosol or other intracellular
compartments of the target cell in order to exert their effect. Hence, the cellular membranes
constitute a large problem for the therapeutic use of these types of drugs. Cells have
complex endocytotic machinery which is responsible for cell signalling, uptake of nutrients,
and disposal of cell debris and pathogens, e.g. bacteria from the tissue environment (Scita,
Di Fiore 2010, Conner, Schmid 2003). There are two main uptake mechanisms i.e.
phagocytosis and endocytosis. Phagocytosis is the primary route used by specialised cells
such as macrophages and their function is focused on the disposal of cell debris and
pathogens; whereas endocytosis is a fundamental process in all cell types. Thus,
endocytosis is a convenient pathway to be exploited in intracellular targeted nanocarriers.
Endocytosis consists of several pathways including macropinocytosis,   clathrin-mediated
endocytosis, caveolin-mediated endocytosis and clathrin and caeolin-independent
endocytosis. Furthermore, the endocytotic process can be stimulated by membrane
adhesion  of  the  nanomaterial  or  it  is  simply  nonspecific  uptake  of  the  surrounding  fluid.
The highest selectivity can be achieved by receptor binding and subsequent receptor
mediated endocytosis. There are studies which have investigated the effect of size and
dimensions on the cell internalisation revealing that the particle size and shape can
influence the uptake rate and mechanism. It was also demonstrated that rod-like
nanoparticles  with  high  aspect-ratios  are  internalized  most  rapidly,  which  might  be  an
evolutionary characteristic to combat bacterial attack (Gratton et al. 2008).
The critical phase for intracellular drug delivery follows after the endocytosis.   Once a
nanoparticle has been internalised in an endocytotic vesicle, it is either recycled out of the
cell or trafficked to organelles including the lysosome, the golgi or the mitochondria,
depending on the mode of internalisation (Chou, Ming & Chan 2011). It has been reported
that mesoporous silica nanoparticles can escape from the endosomes and release their
protein cargo into the cytosol without the need for any lysosome disrupting agents
(Slowing, Trewyn & Lin 2007). Different approaches have been developed so that the
nanocarriers can avoid lysosomal entrapment or lysosomal degradation causeded by
endosome maturation. One technique is to use pH-sensitive polymers, which are able to
disrupt the endosome through so-called proton sponge effect of osmotic swelling (Duan,
Nie 2007, Yezhelyev et al. 2008). Additionally, endosomolytic peptides have been used to
achieve endosomal escape in intracellular delivery with mesoporous silica nanoparticles
(Ashley et al. 2012). The toxicity arising from the disruption of endosomes and lysosomes
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can be reduced by utilising cell penetrating peptides (CPP). Mesoporous silica
nanoparticles have been utilised for the intranuclear delivery of the cancer drug,
doxorubicin, after functionalisation with the HI-virus derived membrane penetrating
peptide TAT (Pan et al. 2012). The cell penetration functionality of nanocarrier can also be a
stimulus activated to enhance the uptake of nanoparticles into the tumour cells, i.e. the CPP
remains hidden until the enhanced protease activity in the tumour cleaves the protecting
shell, exposing the CPP (Olson et al. 2010). Direct penetration of nanomaterials through the
plasma membrane into the cytoplasm is also an attractive route. It has been reported that
small nanoparticles (5 nm) are able to penetrate the cell membrane directly, without
utilising the endocytotic pathway trafficking, when the nanoparticle surface was modified
by altering anionic- and hydrophobic group striations (Verma et al. 2008).
PSi has also been investigated for intracellular delivery applications. PSi nanoparticles
targeted with RDG derived iRDG and RDGS peptides showed efficient uptake into cancer
cells in vitro (Wang et al. 2014). Another recent study has utilized poly(methyl vinyl ether-
alt-maleic acid)-copolymer functionalisation on PSi nanoparticles for enhanced
internalization into cancer cells in vitro (Shahbazi et al. 2014).
1.2.4 Mesoporous particles in drug delivery
The sustained or controlled release of drugs is often an important consideration during the
development of drug carrier systems. The porous matrix enables sustained drug release
since the drug has to diffuse out from the pores. Additionally, the high surface area (>700
m2/g) and the large pore volume (> 0.9 cm3/g) enhances the drug loading capacity. The pore
size can be adjusted to be optimal for the properties of the drug, e.g. hydrophobicity,
molecular weight (Salonen et al. 2008, Vallet-Regí, Balas & Arcos 2007, Santos et al. 2011).
The potential of porous microparticles for drug delivery purposes was first implemented
with molecular sieves made from silicon oxide i.e. silica.  Ibuprofen, an anti-inflammatory
drug, was loaded at 30% (w/w) into the molecular sieves and the release of the drug could
be sustained for days (Vallet-Regi et al. 2001).
At present PSi microparticles have been successfully utilised in the delivery of peptide
hormones i.e. YY3-36, melanotonin II and a ghrelin antagonist (GhA) (Kovalainen et al.
2012b, Kilpeläinen et al. 2009, Kilpeläinen et al. 2011). Additionally, PSi microparticles have
recently been shown to be effective carriers of siRNA for gene silencing (Shen et al. 2013,
Zhang et al. 2014). However, until now similar delivery with PSi nanoparticles has not been
achieved, although mesoporous silica nanoparticles have been utilised for the delivery of
siRNA (Ashley et al. 2012, Na et al. 2012). There is only one study where PSi nanoparticles
have been utilised in peptide delivery in vivo. Interestingly, the PSi nanoparticles were
capable of achieving sustained delivery of GhA peptide, which lasted up to four days after
subcutaneous injection (Kovalainen et al. 2012a). Several studies have been conducted with
small molecular weight drugs incorporated into PSi particles, since this approach can
increase the solubility of poorly-soluble drugs. Table 2 lists some examples of drugs for
which drug delivery with PSi nanoparticles has been investigated.
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Table 2.  The drug delivery of different type of drugs in vivo and in vitro with PSi nanoparticles.
(a) in vitro, (b) in vivo.
Drug Type of drug Reference
Saliphenylhalamide a antiviral Bimbo et al. 2013
Doxorubicin a anticancer Park et al. 2009a
PYY3-36 ab peptide hormone Kovalainen et al. 2012a
Co-delivery of Indomethacin / PYY3-36 a
antiinflammatory / peptide
hormone Liu et al. 2013a
Sorafenib a anticancer Wang et al. 2014
Griseofulvin a antifungal Bimbo et al. 2011
IGF-I ab peptide hormone Huhtala et al. 2012
Furosemide a diuretic Liu et al. 2013b
Splice correcting oligonucleotide a antisense oligonucleotide Rytkönen et al 2014
1.2.5 Opsonisation and the mononuclear phagocyte system
The interactions occuring in the solid-liquid interface between the nanomaterial and the
surrounding biological fluid depend on a series of colloidal forces and dynamic
biophysicochemical actions (Nel et al. 2009). It is clear that these interactions play a crucial
role in the phenomena occurring at the complicated nano-bio interface between the
nanomaterial and biological components (proteins, membrane etc.). When a nanoparticle
enters into the bloodstream, a protein corona is formed on its surface. The protein corona
formation acts as a signal for biological response, e.g. clotting of the blood or phagocytosis
due to altered protein conformations, exposure of new epitopes, perturbed function and
avidity effects arising from the close spatial repetition of the same protein (Cedervall et al.
2007). The surface curvature, which correlates with the size of spherical nanoparticles, plays
a role in the denaturation of the absorbed proteins. For example, lysozyme enzyme
unfolded more when it was absorbed onto larger silica nanoparticles (100 nm) compard to
smaller nanoparticles (4 nm and 20 nm) (Vertegel, Siegel & Dordick 2004). The extent of the
unfolding also correlated with the reduced enzyme activity. The corona formation is a
dynamic process which is determined by the abundance and the binding affinity of the
proteins (Gao, He 2014a).
Opsonins are the proteins that bind to particles in the bloodstream, and enhance
phagocytosis (Owens, Peppas 2006). Since they are part of the immune system, their initial
purpose is to tag foreign material i.e. viruses, bacteria and other particulates for removal by
the mononuclear phagocyte systems (MPS).  The MPS is a family of cells comprising of
bone marrow progenitors, blood monocytes and tissue macrophages that are specialised in
phagocytosis (Hume 2006).  Kupffler cells are a special type of macrophages which live in
direct contact with blood. They are located in the sinusoidal blood vessels of liver and have
a major role in the removal of opsonised particulates from the blood (Frank, Fries 1991).
Blood plasma consists of thousands of different proteins but in most cases the protein
corona is enriched with about 10-50 proteins that have the highest affinity for the
nanoparticle surface (Mahmoudi et al. 2011). The most common opsonins are fibrinogen,
immunoglobulin, alpha-1-antitrypsin and complement factors (Cedervall et al. 2007,
Göppert, Müller 2005, Aggarwal et al. 2009). On the other hand, apolipoproteins and
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albumin are considered as dys-opsonins which prolong the circulation time of the
nanoparticles in the blood. Several other proteins with lower binding affinities take part in
the protein corona formation but they remain unrecognised due to perturbing separation of
particle-protein complexes with centrifugation (Cedervall et al. 2007). The plasma proteins
form a “hard” corona which has slow exchange rate with the environment and on its top
there is a “soft” corona which undergoes more transient interactions with the particle-
protein complex. (Walczyk et al. 2010) Protein adsorption onto limited surface (i.e. corona
formation on nanoparticles) has a competitive nature which is based on abundance,
affinities and time and it is known as the “Vroman Effect” (Göppert, Müller 2005, Vroman
et al. 1980).
A series of studies with polystyrene nanoparticles has revealed that the key elements
which influence the protein binding to nanomaterial are hydrophobicity and the presence
of functional groups. The surface charge itself influences the amount of bound protein but
not the identities of the bound proteins. Furthermoren the size, shape and topology of the
nanoparticles all affect the amount of protein which is bound. (Aggarwal et al. 2009,
Gessner et al. 2002, Gessner et al. 2003) In other studies with mass spectrometry based
identification of the proteins in the corona, the size of the particle has been shown to have
an influence on the type of the bound proteins (Cedervall et al. 2007, Lundqvist et al. 2008) .
The curvature of the surface on small particles reduced the binding of rigid proteins. The
formation of the protein corona affects also the nanoparticle distribution in vivo (Aggarwal
et al. 2009).
The complement system is a cascade which activates the immune response as a part of
the innate immunity and it also contributes to the rapid clearance of nanoparticles from the
systemic circulation via complement mediated phagocytosis by the MPS (Dobrovolskaia et
al. 2008).  It is divided into three main pathways; the classical, lectin and alternative
pathways (Ricklin et al. 2010). The classical pathway is mediated through C1 binding either
to the antigen-antibody complex, pattern recognition molecules such as C-reactive protein
or directly to the surface of pathogen. The lectin pathway is triggered by the binding of
mannose binding lectin to carbohydrates, i.e. mannose, fucose and N-acetylglucosamide on
the surface of the foreign material. The alternative pathway is initiated by the hydrolysation
of C3 or binding of C3b to foreign material. Additionally, it has been reported that
coagulation/fibrinolysis proteases also cleave C3, indicating that there is an interplay
between the complement and the coagulation cascades (Amara et al. 2010). The
complement activation by nanomedicals happens through all of these pathways and the
activation depends on the size, the morphology and the surface properties of the
nanoparticle (Moghimi et al. 2011).
In general, positively charged nanoparticles are more likely to induce inflammatory
reactions (Dobrovolskaia, McNeil 2007). On the other hand, it has been reported that
negatively charged nanoparticles can unfold fibrinogen and promote integrin receptor,
Mac-1 mediated phagocytosis, resulting in the release of inflammatory cytokines
(Dobrovolskaia, McNeil 2007, Deng et al. 2011). The phagocytic cells can utilise several
phagocytic pathways, including mannose receptor mediated-, complement receptor
mediated, immunoglobulin Fc  receptor mediated and scavenger receptor mediated
uptake (Dobrovolskaia, McNeil 2007, Aderem, Underhill 1999). Only scavenger receptor
mediated uptake does not promote a proinflammatory response in the phagocytes.
(Dobrovolskaia, McNeil 2007, Aderem, Underhill 1999)
The opsonisation of PSi microparticles, with different surface charges, changes the
phagocytosis rate in the endothelial cells (Serda et al. 2009). The presence of a protein
corona on oxidized silicon microparticles (negative zeta potential) diminished the uptake
by human umblical vein endothelial cells (HUVEC), whereas amino functionalised particles
(positive zeta potential) were not influenced by corona formation. In contrast to endothelial
cells, J773 macrophages favoured the uptake of negatively charged particles after the
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protein corona formation whereas the phagocytosis of amino functionalised particles was
reduced after opsonisation.
The nanoparticle circulation time can be increased by masking the nanoparticles from
recognition and removal by the MPS. The most commonly used method is to create
hydrophilic poly(ethylene glycol) (PEG) layer on the particle surface that is able to reduce
the absorption of opsonin proteins through steric repulsion (Owens, Peppas 2006).
PEGylation decreases the interaction with blood proteins, enhancing the circulation time. A
recent study with pDNA poly-L-lysine polyplex micelles reported that the PEG grafting
density was directly linked to the blood circulation time (Tockary et al. 2013). The PEG
density affected also the uptake mechanism by macrophages (Walkey et al. 2012). If the
PEG density was more than 0.64 (PEG/nm2) then the phagocytosis became serum
independent. However, even with higher density, PEG could not completely eliminate the
cell  uptake.  Opsonisation is  virtually  unavoidable  for  the  nanoparticles  when they are  in
the blood. However, it can also be turned to an advantage. It has been reported that
conjugation of apolipoproteins to albumin nanoparticles enhanced their accumulation into
the brain (Kreuter et al. 2007).
The protein corona composition after a short immersion in human plasma has been
studied extensively also with PSi nanoparticles with varying surface functionalisations
(Rytkönen et al. 2012, Sarparanta et al. 2012, Näkki et al. Submitted, Wang et al. Submitted).
PEGylation reduced the binding of proteins in human blood plasma but did not change the
protein composition, whereas binding of fungal protein hydrophobin II altered the protein
fingerprint by reducing fibrinogen binding, thus contributing to the binding of
apolipoproteins (Table 1.)
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Table 1. Detected proteins bound to different surface stabilised and modified PSi nanoparticles.
Not detected (-), detected (+), abundant (++). The abundancy of the proteins is estimated
from the images of the electrophoresis gels. Modified from Rytkönen et al 2012, Sarparanta et
al 2012, Näkki et al submitted, Wang et al submitted.
Proteins bound to nanoparticles
Immunoglobulin M ++ + - + ++
Immunoglobulin G ++ + ++ ++ ++ + ++ +
Complement 1 + - - - - -
Complement 3 + - - + + -
Fibrinogen + + ++ - ++ + ++
Serum albumin ++ + + - ++ + ++ -
Clusterin - - - +
Plasminogen ++ - - -
Inter- -trypsin inhibitor - - + + +
Histidine-rich glycoprotein ++ - - - -
Serotransferrin - - + - - - -
Apolipoprotein A-I ++ + + + +
Apolipoprotein A-IV + - - + -
Apolipoprotein B-100 - - - - -
Apolipoprotein C I-III +
Apolipoprotein E ++ + - + +
1.2.6 Toxicity issues of nanomedicines
The development of safe materials for nanomedicine has to be based on a detailed
understanding of the biological interactions at the cellular level. The main corcerns for
public health with nanomaterials originate from chronic low dose toxitity exposures
conducted as soot and other ultrafine particle exposures administered in aerosols
(Elsaesser, Howard 2012). However, in nanomedicine, chronic exposure is not as relevant
as the short term exposure to relatively high doses, which may cause acute toxicity. Until
now, nanomedical research has focused mostly on the effect that the body has on the
nanocarrier e.g. opsonisation and circulation time in vivo. However, the impact of the
nanomaterial on the body (e.g. inflammation, toxicity and hypersensitivity) also needs to be
addressed.
PSi nanoparticles are considered as biocompatible based on in vitro studies with cell
cultures (Bimbo et al. 2011, Bimbo et al. 2010). However, the surface functionalisation is also
an important factor in the cytotoxicity evoked by the nanoparticles. The toxic effects of PSi
nanoparticles are predominantly surface charge dependent whereas the
hydrophophilic/hydrophobic surface properties have less influence (Shahbazi et al. 2013).
However, hydrophobic surfaces seem to be slightly more cytotoxic when the surface charge
is the same as with hydrophilic nanoparticle surfaces. Additionally, amino functionalised
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PSi nanoparticles induce the highest reactive oxygen species (ROS) response. The role of
surface charge and geometry in acute toxicity in vivo has been studied with mesoporous
and nonporous silica nanoparticles (Yu et al. 2012). The hydrodynamic size of the
nanoparticle after opsonisation has been found to determine the acute toxicity in mice. The
larger the hydrodynamic size of the opsonised nanoparticles, the lower is the maximum
tolerated dose. Large particles can cause obstructions in the vasculature leading to
congestion in vital organs. However, the mice tolerated substantial doses of nanoparticles
as the maximum tolerated dose varied between 30-450 mg/kg with different types of
surface chemistries.
After systemic injection, it may take some time before the nanoparticles are excreted
from the body, thus the long term toxicity of nanoparticles and their dissolution products
needs to be kept in mind when designing a nanocarrier system for biomedical applications.
In vivo biocompatibity studies in rats show that the PSi nanoparticles induce mild changes
in the spleen, the kidneys, and the liver within 24 hours after a bolus injection (0.7 mg/kg)
(Shahbazi et al. 2013). Hemocompatibility studies have shown that the red blood cell
deformation is highly dependent on the surface charge of the PSi nanoparticles. Another
study showed that PSi microparticles are well tolerated with HUVEC cells in vitro
(Martinez et al. 2013). The in vivo studies with the PSi microparticles show only mild
elevations in cytokine levels returning to normal within 3 days. The histologic evaluation of
internal organs revealed a reversible liver damage in mice when this was evaluated even
months after the intravenous injections of PSi microparticles.
Intravenously administered nanoparticles have been thought to cause adverse
cardiovascular effects through several mechanisms e.g.; direct nanoparticle interactions
with the cells of cardiovascular system, tissue injury at the site of exposure with generation
of inflammatory/oxidative responses which are propagated throughout the circulation or
interactions with the sensory nerve endings at the site of exposure and subsequent
dysregulation of autonomic cardiovascular reflexes (Mann et al. 2012). Hypersensitivity
reactions, i.e. anaphylactic and anaphylactoid reactions, are another form of malignant
acute reactions potentially encountered with intravenously administred nanomedicines.
They have very similar symptoms but their triggering mechanism is different (Salo 2003).
The anaphylactic reaction is immunologic whereas the anaphylactoid reaction is caused by
direct complement activation and the subsequent release of anaphylatoxins, which in turn
activates mast cells to release histamine. Thus, the reaction has been named as the
complement activation-related pseudoallergy (CARPA). This differs from the category I
hypersensitivity reactions, described by Coombs and Gell in the 1960s (Rajan 2003, Szebeni
et al. 1999, Szebeni 2005). It is not mediated by pre-existing IgE antibodies, meaning that no
presensitation is needed for the reaction and the response decreases rather that increases
with repeated exposure. It has been reported that nearly 10% of patients treated with Doxil
and Ambisome, liposomal doxorubicin and amphotericin B, experienced cardiovascular
distress symptoms during an infusion, such as shortness of breath, tightness in the chest or
dizziness (Janssen Products 2014, Szebeni et al. 2000, Alberts, Garcia 1997, Ringden et al.
1994). In most cases, the symptoms were mild and could be avoided by reducing the
infusion rate but in hypersensitised patients consequences may be fatal. Thus, the
susceptibility of the individual patient towards hypersensitivity reactions should be
analysed prior to the treatment. Szebeni et al. described an increase in pulmonary blood
pressure and a decline in the systemic arterial pressure and cardiac output after a bolus
injection of liposomal Doxil and AmBisome in pigs (Szebeni et al. 2006, Szebeni et al. 2012).
Complement activation has been recognized as the key element in CARPA mediated
hypersensitivity reactions (Szebeni et al. 2006, Szebeni et al. 2012, Miller et al. 2012).
Interestingly complement activation is present even when using PEGylated micelles
(Szebeni 2005).
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In another recent study conducted in rats, several different types of nanoparticles were
found to have similar impacts on the cardiovascular system but the mechanism was
proposed as not being inflammatory (Vlasova et al. 2014). A bolus injection of PSi
nanoparticles and polymeric nanoparticles with different surface chemistries and carbon
nanotubes reduced the mean arterial blood pressure and increased the heart rate in
conscious rats (~16.6 mg/kg). Interestingly, it was reported that different mechanisms of
action were involved with the different nanomaterials, i.e. either from nanoparticle-induced
endothelium dependent or independent vasodilation as well as changes in the constriction
and dilator responses of the blood vessels. Even tough there was clear hypotension, there
were no lethal complications following a bolus injection.  Another study with so-called
Langendorff Heart, an isolated guinea pig heart, demonstrated that synthetic nanoparticles
could stimulate the sympathetic nerves in the heart to release catecholamines which
increased the heart rate. This effect could last for hours even after removal of the
nanoparticles (Stampfl et al. 2011).
It is important to remember that seemingly nontoxic nanomaterials in vitro can  have
unexpected effects in vivo,  i.e. the in vitro biocompatibility does not always fully correlate
with actual in vivo biocompatibility  and  this  issue  always  should  be  assessed  thoroughly
with nanomedicals (Dobrovolskaia, McNeil 2013).
1.2.7 Imaging
The rationale of using nanoparticles for molecular imaging is the improved contrast over
traditional contrast agents. Additionally, their pharmacokinetics can be controlled by
varying their size, surface properties and shape (Moghimi, Hunter & Andresen 2012). The
concept of theranostics is based on the imaging potential of nanoparticles and the
diagnostic information they can provide (Kelkar, Reineke 2011).
PSi nanoparticles are suited for optical imaging purposes due to their intrinsic near-
infrared photoluminescent properties which are based on the quantum confinement effect
(Park et al. 2009a). However, the photoluminescence is heavily dependent on the pore wall
thickness and the surface chemistry and is not a fixed feature of PSi.  Additionally, the
surface functionalisation of PSi nanoparticles with fluorescent probes allows their
utilisation in fluorescence microscopy (Xu et al. 2012a).  Photoluminescent- and fluorescent
imaging techniques are convenient methods for in vitro studies, even for preclinical in vivo
imaging. However, optical imaging has only a limited potential in clinical imaging due to
the poor tissue penetration and quenching of the emitted light. However, the well
developed surface chemistry of PSi also permits the conjugation of radiotracers to the PSi
nanoparticles which enables even clinical imaging with PSi nanoparticles. Positron
emission tomography (PET) imaging of PSi nanoparticles is possible after modifying the
surface with 18F-isotope (Sarparanta et al. 2011). Simple conjugation of the amino acid,
tyrosine, onto the PSi surface allows the labelling of the nanoparticles with iodine
radioisotopes, opening new imaging possibilities (Rytkönen et al. 2012). 131I and 125I can be
utilized in single photon emission computed tomography (SPECT) imaging. In addition to
the radioisotope based imaging techniques, PSi nanoparticles have been modified also for
magnetic resonance imaging (MRI) and for X-ray based computed tomography (CT)
imaging.  A novel method to incorporate magnetic iron oxide nanoparticles inside the
porous matrix allows the use of the PSi nanoparticles as a contrast agent with both
techniques (Nissinen et al. 2014).
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2 Aims of the study
Nanostructured silicon has been found to be asuitable material for controlled drug release,
whereas the use of PSi nanoparticles for drug delivery is still a rather unexplored research area.
The general objective of the study was to develop PSi nanoparticle based drug delivery carriers
emphasising safety, imaging and gene therapy aspects. The specific aims of the study were as
follows:
1. To develop functionalisation methods for the PSi nanoparticle surface which would
facilitate the targeting and the imaging of the PSi drug carriers. (Papers I and II)
2. To evaluate PSi nanocarriers in intravenous peptide delivery by studying the
pharmacokinetics and the physiological effects of the peptides and the carriers after
systemic administration (Papers II, III and IV)
3. To study the intracellular delivery of drugs with PSi nanocarriers (Papers II and V)
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3 General methodologies
This section shortly describes some of the methods used. More detailed descriptions of the
experiments can be found in the published articles mentioned in parentheses.
3.1 NANOPARTICLE HANDLING AND CHARACTERISATION
3.1.1 Nanoparticle preparation
PSi nanoparticles used in the studies were prepared by electrochemically etching (p+)–type
single crystal silicon wafers (100) in HF/EtOH mixture. The porous silicon films were surface
stabilised and ball milled into nano- and micro sized particles. Afterwards, the particles were
size fractioned by using sieving or centrifugation procedures. Additional surface
functionalisations were conducted in order to incorporate functional groups on the particle
surface onto facilitate further conjugation of molecules on the PSi surface. The different surface
stabilisations and functionalisations used in the experiments are listed in Table 3.
Table 3. The physical properties of the PSi nanoparticles used in the experiments.
3.1.2 Nanoparticle handling
The PSi nanoparticles were stored in organic solvents, such as EtOH or dimethyl formamide
(DMF) to reduce oxidation. Changing of the solvent was done by centrifuging the nanoparticles
down to a pellet in a plastic laboratory tube and resuspending the nanoparticle pellet in a
suitable solvent. The process was repeated at least three times to remove all residues of the
previous solvent. This process is later referred to as the “washing” of the nanoparticles. Due to
the slow oxidation and dissolution of the nanoparticles in the aqueous environment, the
nanoparticles were used for experiments within 24 hours after they were placed to aqueous
solutions. All the water used in the experiments was ultrapure grade if not stated otherwise.
3.1.3 Surface conjugation
The surface conjugation of carboxylic acid functionalised nanoparticles was conducted in DMF
using N,N’-diisopropylcarbodiimide (DIC) and N-hydroxysuccinimide (NHS) chemistry (Paper
Surface stabilisation Functional groups
Hydrodynamic
size (nm)
Zetapotential
(mv) Paper
THCPSi, hydrosilylated COOH 140 -31.7 I
Hydrosilylated (internal surface),
TOPSi (external surface)
COOH (internal surface),
Folic acid (external surface) 211 -10.7 II
THCPSi - 110 +6.5 III, IV
TOPSi NH2 190 +55.6 V
TCPSi NH2 173 +49.3 V
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I). Briefly, the nanoparticles were reacted with 40 mM NHS and DIC in DMF for 1 hour at room
temperature enabling the formation of succinimide esters. The activated nanoparticles were
washed with acetonitrile and stored prior to later use. The succinimide esters react easily with
molecules containing primary amino groups allowing conjugation of targeting antibodies,
aminated PEG or tyrosine for radiolabelling. The activated nanoparticles were mixed with the
molecules with which they would be conjugated in aqueous solution for 30 minutes at room
temperature. The nanoparticles were washed to remove excess reagents and the conjugated
nanoparticles were dispersed into a suitable medium.
3.1.3 Fluorescent labelling
In order to visualise the intracellular trafficking of amino functionalised PSi nanoparticles with
confocal microscopy, they were labelled with fluorescein 5-isothiocyanate (FITC) (Papers II and
V). Briefly, the nanoparticles (0.5 mg/ml) were suspended into FITC-solution (0.001mg/ml in
EtOH) and allowed to react in the dark for 18 hours at room temperature. Afterwards; the FITC-
labelled nanoparticles were washed with EtOH and water
3.1.4 Nanoparticle characterisation
The nanoparticles’ size, zetapotential, and morphology were regularly characterised with
dynamic light scattering (DLS) (Papers I, II, IV and V) and transmission electron microscopy
(TEM) (Papers I, II and V). The zeta potential and the hydrodynamic size of the nanoparticles
suspended in water were measured with Malvern Zetasizer Nano ZS (Malvern, Southborough
MA, U.S.A.) The TEM samples were prepared by drying the nanoparticle sample on Formvar-
resin coated copper sample grids of mesh size 200. The images were taken with JEM-2100F
(JEOL, Tokyo, Japan) using an acceleration voltage of 200 kV.
3.2 RADIOLABELLING WITH IODINE-125
Radiolabelling is essential for quantitative in vivo tissue distribution studies and
autoradiography. Furthermore, it can also facilitate peptide loading and release studies with
nanoparticles. The nanoparticles and the peptides were labelled with gamma emitting isotope
of iodine (125I) onto tyrosine and histidine amino acids which can be readily iodinated since they
have aromatic side chains susceptible to electrophilic substitution.
3.2.1 Peptide radiolabelling and purification
The ghrelin antagonist (GhA) [H-(D)W-(D)K-W-(D)F-K-NH2) is a small 0,9 kDa synthetic
peptide that reduces appetite and therefore has been speculated as being useful in the treatment
of obesity. Another polypeptide, insulin like growth factor 1 (IGF-1)
(GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCA
PLKPAKSA) is 7.6 kDa hormone stimulating cell proliferation and differentiation, especially
during embryonic and postnatal development.
The peptides were radiolabelled with Na125I using chloramine-T (Paper IV) or Pierce
Iodogen® (Thermo Scientific) tubes which have been precoated with water insoluble oxidizing
agent (Paper III). Briefly, the radio-iodide was oxidised and allowed to react with the peptide in
phosphate buffer for 15 minutes at room temperature. The 125I-labelled  GhA  peptide  was
purified with reversed-phase high-performance liquid chromatography (HPLC) on C18 column
(Phenomenex Jupiter 10µm C18 300a) using a gradient of acetonitrile/water containing 0.1%
trifluoroacetic acid. The 125I-labelled IGF-1 peptide was purified with size exclusion
chromatography using HiTrap Sephadex column (GE Healthcare, Sweden). The peptides’
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radiochemical purities were analysed with thin layer chromatography or analytical HPLC
before further use.
3.2.2 Radiolabelling of the nanoparticles
The radiolabelling of UnTHCPSi nanoparticles with 125I was enabled by electrophilic addition of
iodine on the phenol ring of the amino acid tyrosine on the surface of the nanoparticle. The
nanoparticles were radiolabelled using the Pierce Iodogen method (Paper I). The radiolabelled
nanoparticles were purified from the unreacted iodine by washing with water.
3.3 LOADING AND RELEASE STUDIES
The porous structure of PSi nanoparticles and the versatile surface chemistry allow efficient
drug loading based on electrostatic and hydrophobic interactions. Fluorescent or radiolabelled
molecules were utilised in the loading/release studies.
3.3.1 Anti-cancer drug doxorubicin
Anti-cancer drug doxorubicin was loaded into selectively modified PSi particles (Paper II).
Briefly, the PSi particles (25 mg/ml) were immersed into aqueous solution of doxorubicin (10
mg/ml). After stirring for 12 hours, the drug-loaded PSi particles were filtered and dried at 65
°C for 4 hours. The drug loading degree was determined using a thermal gravimetric
measurement (PerkinElmer). The release experiments of doxorubucin were performed in
phosphate- and acetate buffer (pH: 7.4 and 5.0 respectively) at 37 °C. The doxorubicin loaded
particles were dispersed into buffer solution (2 mg/ml). At predetermined time points, 0.5 ml of
the release media was taken for analysis by centrifuging the total volume of 10 ml and
additionally, the same volume of fresh buffer solution was added into the system. The
concentration of the doxorubicin in the release media was determined with a UV-Vis
spectrophotometer at 478 nm (JASCO V-530).
3.3.2 Peptides
The peptides were loaded into the nanoparticles in aqueous solutions (Papers III and IV).
Briefly, the nanoparticles were dispersed into peptide solution. The peptide – nanoparticle ratio
was 1:4. The loading was carried out for 2 hours by mixing the vessel every 30 minutes at room
temperature. The loading efficiency was calculated by measuring the concentration of the
remaining radioactive peptide from the supernatant with a gammacounter.
The in vitro release was studied using fresh plasma diluted 1:2 in phosphate buffered saline.
Nanoparticles were incubated in plasma at +37 °C with constant mixing. A sample of the
particles was centrifuged at predetermined time points. The release of the peptide was
determined by measuring the radioactivity in the supernatant with a gammacounter.
3.3.3 Oligonucleotide
Splice correcting oligonucleotides were loaded into positively charged PSi nanoparticles (Paper
V). The fluorescent labelled (Cy5) oligonucleotides (1 µM) were dissolved in water. In order to
obtain the optimal loading degree, different nanoparticle concentrations were utilised i.e.  0.00;
0.02; 0.04; 0.06; 0.08 or 0.10 mg/ml. The mixture was vortexed, incubated for 5 minutes at room
temperature and centrifuged for 15 minutes using 13 200 rpm (Eppendorf Centrifuge 5425,
Eppendorf AG, Hamburg, Germany). In the measurement of the loading degree of Cy5-
oligonucleotide in the PSi nanoparticles, a sample of the supernatant was taken and measured
in a fluorometer (Fluoroskan Ascent FL, Labsystems, Turku, Finland).
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3.4 CELL STUDIES
3.4.1 Cell culturing
The cells, HeLa (Paper II) and HeLa pLuc 705 (Paper V), were cultured in Dulbecco´s Modified
Eagles’s Medium supplemented with 10% fetal bovine serum, 0.1% L-glutamine, and 0.1%
penicillin / streptomycin antibiotics. The incubation temperature was kept steady +37 °C and
the pH was stabilised with 95% air, 5 % CO2 atmosphere. The cells were passaged when they
reached confluence and the experiments were conducted using cells between passages 3-25.
3.4.2. Cell viability assays
The effect of nanoparticles on the cell proliferation was investigated either by using colorimetric
reaction of (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) assay, based on presence of the reducing enzymes in viable cells (Paper V) or
luminescent CellTiter-Glo® based on the adenosinetriphosphate present in viable cells (Paper
II). Briefly, the cells were seeded on 96-well plate 24 hours before incubation with nanoparticles
(10 000 cells / well). After the incubation, the cell viability was measured either immediately or
after a 48 hour incubation perioid in a Tecan Sunrise™ microplate reader (Tecan Trading AG,
Switzerland) at the wavelength of 450 nm or in aluminometer Fluoroskan Ascent FL
(Labsystems, Turku, Finland). The reagents were used according to the manufacturer’s
instructions.
3.4.3 Confocal scanning laser microscopy
The internalisation and intracellular trafficking of FITC-labelled PSi nanoparticles were
visualised in a confocal microscope (Papers II and V). The cells were seeded onto a 8-chamber
cover glass and were allowed to attach for 24 hours before their treatment with the
nanoparticles. After the incubation with the studied nanoparticles, the cells were washed with
fresh and warm medium or buffer. Additionally, fluorescent stains were used to detect different
cell compartments, including Hoechst 33342 for nuclear staining and Lysotracker® Red DND-
99 for endosome and lysosome staining. The cells were imaged live with LM 700 Confocal Laser
Microscope (Zeiss, Germany).
3.5 ANIMAL STUDIES
All experiments with animals were conducted in accordance with the guidelines set by the
Finnish Act on Animal Experimentation (62/2006) and European Community Council
Directives 86/609/EEC. The National Animal Experiment Board of Finland approved the
experiments. The mice and rats received chow and water ad libitum and were housed in 12 h/ 12
h light-dark cycle.
3.5.1 Tissue distribution studies
The 125I-labeled samples, in isotonic solution, were administered via tail vein injection or
through a catheter inserted in the jugular vein (Papers I,III,IV). If the animal needed to be
anesthetised prior to the injection then 1.5 – 2.0 % isoflurane gas flow was used. Animals were
sacrificed at the predetermined time point after the injection and tissue samples were collected
in pre-weighted tubes. The radioactivity was measured using an automated gamma counter
(Clinigamma, Wallac, Finland). Corrections were made for background radiation and physical
decay during counting. The activity in all organs and tissue samples was expressed as a
percentage of injected dose per gram of tissue (%ID/g).
23
4 Results and discussion
The main results are presented and discussed in this chapter. The more detailed results
including tables and figures can be found in the original published articles mentioned in
parentheses.
4.1 SURFACE FUNCTIONALISATION OF PSI NANOPARTICLES
The versatile surface chemistry of silicon allows various hydrophilic and hydrophobic surface
stabilisations and functionalisations of PSi particles. This enables additional functionalisation
with shielding polymers or targeting ligands. Furthermore, the surface can be tuned for
different therapeutic molecules to optimise the loading degree.
The carboxylic acid functionalised UnTHCPSi nanoparticles form amide bonds with amino
groups containing molecules by utilising simple EDC/NHS chemistry. UnTHCPSi nanoparticles
were successfully functionalised with different sized PEG molecules and targeting antibodies.
Furthermore, the conjugation with the tyrosine amino acid enabled the labelling of the
nanoparticles with radioisotopes of iodine. (Paper I) The surface functionalisation with different
surface chemistry on the external and internal surfaces allowed conjugation of targeting ligand
only to the external surface. The internal surface was left optimal for drug adsorption in an
attempt to improve the drug loading degree. (Paper II)
4.2 TISSUE DISTRIBUTION OF PSI NANOPARTICLES
The circulation time of UnTHCPSi nanoparticles in blood is very short. The radioactivity
decreased in the blood from 35% ID/g to 2% ID/g within ten minutes after the injection. The
majority of the nanoparticles accumulated into liver and spleen tissue almost instantly (Paper I,
Table 5). The poor circulation time is due to strong opsonisation of the nanoparticles in the
bloodstream and the following removal from the circulation into the liver. However, when
studied with microscopic autoradiography, the nanoparticles were shown to remain mostly in
the lumen of the hepatic sinusoids 10 minutes after the administration (Paper I, Figure 6).
4.3 DRUG LOADING
Different types of drug molecules were loaded into PSi nanoparticles (Papers II, III, IV, V). The
corresponding drug molecules and their loading degrees are presented in Table 4. Larger
biomolecules, i.e. peptides and oligonucleotides, are easily loaded into PSi nanoparticles by
using hydrophobic and electrostatic interactions. The large size provides more interactions with
the particle surface enabling substantially higher loading efficiencies compared to drugs with
small molecular weight. The loading efficiency of the small molecular weight doxorubicin is
poor and a high concentration of the drug molecule has to be used in the loading process in
order to achieve a reasonable drug loading degree.
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Table 4. Loading degrees and efficacies of different drugs loaded into PSi nanoparticles.
Drug name Drug type
Loading
efficacy (%)
Loading
degree (%,
w/w) Paper
Doxorubicin anti-cancer drug 6.9 2.7 II
Insulin-like growth factor 1
(IGF-1) peptide 94.0 23.5 III
Ghrelin antagonist (GhA) peptide 85.5 21.4 IV
Splice correcting
oligonucleotide
antisense
oligonucleotide 100.0 14.7 V
4.3 IN VITRO DRUG RELEASE
4.3.1 Peptide release
The release of 125I-labelled peptides from THCPSi nanoparticles was studied in fresh plasma.
Both peptides (GhA and IGF-1) showed a strong burst release immediately after their
immersion in plasma. With IGF-1 peptide, the release continued for two hours before reaching a
plateau where no release was taking place. Nearly 40% of the peptide still remained in the
nanoparticle after four hours of incubation. (Paper III, Figure 1.) Burst release was dominant
also in the case of GhA peptide. Nearly 75% of the peptide was released from the nanoparticle
within the first 15 minutes of incubation. No further release was observed during the ten hour
monitoring. (Paper III, Table 1.) The fast release of peptides from the nanoparticles in blood
plasma was most probably caused by displacement from competing protein binding.
4.3.2 Doxorubicin release
Optimal situation for drug delivery is achieved when the drug is released only at the targeted
site. This is especially crucial with anti-cancer drugs which can cause severe side-effects. The
anticancer drug, doxorubicin, was loaded into PSi nanoparticles with separately engineered
external and internal surfaces. Carboxylic acid surface functionalisation in the pores achieved
pH-dependent release of doxorubicin from the pores. At normal physiological pH 7.4 the drug
is released only in small quantities remaining below 20% in 24 hours. When the pH was
reduced to 5.0, like in the lysosomal compartments that particle will encounter after cellular
uptake, the drug release was faster reaching over 50% after 5 hours (Paper II, Figure 5).
Furthermore, it was found that thethe different surface chemistries on the external and internal
surfaces had contributed to the loading of the drug only inside the pores as the
functionalisation on the external surface was less suitable for drug adsorption.
4.4 SYSTEMIC DELIVERY
THCPSi nanoparticles were utilised in the delivery of two peptide hormones in vivo. The
distribution and pharmacokinetics of IGF-1 peptide were studied with 125I-radiolabelling,
whereas the monitoring of GhA peptide delivery was based on its physiological effects, i.e.
cardiovascular changes.
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4.4.1 IGF-1 peptide delivery
The pharmacokinetics of IGF-1 peptide was studied using a free peptide solution, bound to a
carrier protein (insulin-like growth factor binding protein 3, IGFBP-3) or loaded into THCPSi
nanoparticles. The pharmacokinetics of the peptide changed dramatically when it was loaded
into PSi nanoparticles. The clearance of IGF-1 through the kidneys was reduced substantially
using the nanoparticles compared to the free or IGFPB-3 bound IGF-1. On the other hand, a
higher concentration was detected in the liver and in the spleen as a consequence of
nanoparticle aided administration (Paper III, Figure 2a). The concentration of nanoparticle
loaded IGF-1 was more constant in all tissues except liver and spleen.  Additionally, the peptide
concentrations were lower when compared free peptide solution or carrier protein bound
peptide, pointing to a more efficient removal of nanoparticles from the systemic circulation
(Paper III, Figure 2b).
4.4.2 GhA peptide delivery and adverse effects of THCPSi nanoparticles
GhA peptide delivery in rats was monitored with telemetric measurements to assess its
cardiovascular effects, i.e. elevation of systemic blood pressure and heart rate. Systemic
administration of GhA (2.5 mg/kg) elevated both the systemic blood pressure and the heart rate
and the effect lasted for several hours. On the other hand, THCPSi nanoparticles reduced the
blood pressure and increased the heart rate of conscious rats after a bolus injection.  When
loaded with GhA, the particles negated the effect of peptide hormone on the blood pressure.
Both GhA and the nanoparticles elevated the heart rate when administered separately.
Interestingly, there was no additive nor synergistic effect from the GhA loaded nanoparticles on
the heart rate. (Paper IV, Figure 3)
The effect of THCPSi on the heart rate was blocked by the prior administration of -blocker
atenolol. However, the effect of reduced systemic blood pressure remained, suggesting the
involvement of a different mechanism of action. (Paper IV, Figure 3) Notably, the bolus
injection with THCPSi nanoparticles did not induce any major inflammatory reactions in the
rats, as no cytokine release was detected (Paper IV, Figure 4).
4.5 TARGETED DELIVERY
PSi nanoparticles were demonstrated to be easily functionalised with the targeting ligand and
were shown to be selectively delivered to their target site. Selective delivery of drugs is a
necessity for nanomedical application of PSi nanoparticles.
UnTHCPSi nanoparticles conjugated with targeting antibodies were demonstrated to posses
targeting ability to their antigen protein in the immunoprecipitation assay conducted in human
plasma. The antibody towards glutathione S-transferase (GST) improved the binding of
UnTHCPSi nanoparticles to GST-bound agarose by nearly 35-fold in 15 minutes as compared to
nonspecific human IgG-targeted nanoparticles. (Paper I, Page 6) The assay was conducted in
human plasma demonstrating an operative targeting functionality in a very challenging
physiological environment.
The folate receptor is overexpressed on the apical surface of several cancer types, thus
targeting with folic acid represent a feasible method to enhance selective delivery into cancer
cells. PSi nanoparticles were targeted with folic acid into HeLa cancer cells, which overexpress
the folate receptor. The uptake of folic acid targeted nanoparticles was evaluated with a flow
cytometer and confocal microscopy. The uptake of nanoparticles was shown to be partially
mediated through the folate receptor as the internalisation could be reduced in the presence of
competing free folic acid in the culture medium (Paper II, Figure 6 and Figure 7).
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4.6 INTRACELLULAR DELIVERY
The intracellular delivery of cancer drugs can reduce the side-effects if the target cells can be
distinguished from healthy cells. Folic acid targeting increased the uptake of PSi nanoparticles
into HeLa human cancer cells through folate receptor mediated endocytosis. The nanoparticles
were seen coalescent with lysosomes in the confocal microscopy study (Paper II, Figure 7). The
endosomal compartments of target cells, with reduced pH, are the desired accumulation site for
nanoparticles which express pH-dependent release of the doxorubicin cargo.
HeLa cell line with stable gene expression of luciferase enzyme with a mutation promoting
aberrant splicing of pre-messenger RNA provided a convenient tool for evaluating the
intracellular delivery of oligonucleotides. Splice correcting oligonucleotide (SCO) can prevent
the normally occurring aberrant splicing resulting with fully functional luciferase enzyme.
However, SCO needs to enter the cytosol and the nucleus before it can exert its effect. PSi
nanoparticles functionalised with CPP were used to deliver SCO into the cytosol of cancer cells.
Without the functionalisation with CPP, the SCO loaded nanoparticles were also readily
internalised to the cells but no biological response from SCO was observed. (Paper V, Figure 5
and Figure 6). SCO could also be delivered into the cells using only CPP which aids the SCO to
penetrate through the cell membranes into the cytosol. However, by protecting the cargo within
the pores of PSi nanoparticles it could be rendered more resistant against degradation by
proteases and nucleases (Paper V, Figure 7).
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5 Conclusions
The present study describes the development of drug delivery vehicles based on PSi
nanoparticles for nanomedical applications. The results lead to following conclusions.
1. The nanoparticle surface could be easily modified to contain targeting molecules, i.e.
antibodies or folic acid, as well as PEG polymer coating, which reduced the opsonisation
of the particles. Additionally, a feasible method for conjugation of imaging tracers was
developed.
2. PSi nanoparticles were found to be suitable for peptide delivery as they permitted
manipulation of the pharmacokinetics of the peptide being administered within the
nanoparticles. Furthermore, the peptides maintained their biological effects when
delivered within the nanoparticles.
3. The nanoparticles by themselves could exert effects on the cardiovascular function of rats
after a bolus injection without an inflammatory reaction. The mechanism of action for
reduction of blood pressure by the THCPSi nanoparticles remained to be clarified.
4. Specific uptake into the endosomal compartments of cancer cells and following pH-
dependent release of the cargo could be achieved with PSi nanoparticles. Furthermore,
PSi nanoparticles were found to be suitable for the intracellular delivery of antisense
oligonucleotides preserving their biologically active form.
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6 Future perspectives
Functionalised mesoporous silicon nanoparticles have shown interesting properties in drug
delivery and imaging, and have demonstrated their ability to work as targeted nanomedicals.
The results here provide fundamental knowledge about the development of drug delivery
devices and have examined some of the major problems that one may encounter in the
nanomedicine development process. Opsonisation and the activation of the immune system are
still the greatest challenges preventing efficient nanoparticle-based drug delivery systems.
Opsonisation can hinder the targeting and the efficient removal by immune system may
seriously impair the delivery. Thus, gaining a deeper knowledge of the interaction between
nanomedicals and the biological environment is essential for future research. The nanocarriers
themselves can have unexpected effects on the patient physiology. Therefore, more resources
need to be provided into developing in vitro toxicity techniques which would be cheap and
have a high throughput but which would correlate with the more costly and time consuming in
vivo studies.
Controlled and sustained release of the drug molecules represents the rationale behind drug
delivery applications. Therefore, novel and more efficient utilities for triggered release of the
cargo need to be developed. One possible direction is to utilize so-called multistage carriers
which would be activated, for example, by physiological stimuli and release second stage
nanocarriers which could then home onto their target site and treat the disease in question. In
conclusion, the field of nanomedicine has advanced significantly and it seems likely that novel
drug delivery vehicles will be approved and marketed in the near future.
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